OncoStem Diagnostics
OncoStem Diagnostics Pvt. Ltd develops innovative prognostic tests for cancer, focusing on personalized treatment plans by assessing tumor biology. Their flagship product, CanAssist Breast, uses a proprietary AI-based model to predict the risk of breast cancer recurrence over five years, classifying patients as low or high risk to guide chemotherapy decisions. Validated in multi-centric clinical studies and accredited labs, the test is trusted by over 300 oncologists across South Asia and aims to improve quality of life by avoiding unnecessary chemotherapy. The company operates a CAP and NABL accredited reference laboratory in Bengaluru and continues research to develop novel tests for other cancers.
OncoStem Diagnostics
OncoStem Diagnostics Pvt. Ltd develops innovative prognostic tests for cancer, focusing on personalized treatment plans by assessing tumor biology. Their flagship product, CanAssist Breast, uses a proprietary AI-based model to predict the risk of breast cancer recurrence over five years, classifying patients as low or high risk to guide chemotherapy decisions. Validated in multi-centric clinical studies and accredited labs, the test is trusted by over 300 oncologists across South Asia and aims to improve quality of life by avoiding unnecessary chemotherapy. The company operates a CAP and NABL accredited reference laboratory in Bengaluru and continues research to develop novel tests for other cancers.